We are studying whether early treatment with Rituximab can help prevent EBV infections and related complications in kidney transplant recipients who are EBV negative. This research aims to improve outcomes for patients receiving organs from EBV positive donors.
Health conditions and diseases that the clinical trial is designed to study and treat.
Epstein-Barr Virus (EBV) is a common virus that can cause complications in kidney transplant patients, potentially leading to issues like organ rejection or lymphoproliferative disorders. It's crucial for transplant recipients to be monitored for EBV to manage their health effectively.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.